Trial · NCT07335081
ctDNA in HER2+ EBC Neoadjuvant Treatment
NCT07335081, Phase 2, Recruiting, Shanghai Jiao Tong University School of Medicine
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. ctDNA in HER2+ EBC Neoadjuvant Treatment. Trials, record NCT07335081. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07335081
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- ctDNA in HER2+ EBC Neoadjuvant Treatment
- NCT number
- NCT07335081
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 60 participants, estimated
- Lead sponsor
- Shanghai Jiao Tong University School of Medicine
- Conditions
- Breast Cancer
- Interventions
- pyrotinib, pertuzumab, trastuzumab, docetaxel
- First posted
- 2026-01-12
- Last updated
- 2026-03-24
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | ctDNA clearance after one cycle neoadjuvant treatment | 3 months after neoadjuvant treatment initation | The rate of ctDNA clearance after first cycle of neoadjuvant treatment |
| Secondary | ctDNA clearance after two cycle neoadjuvant treatment | 3 months after neoadjuvant treatment initation | The rate of ctDNA clearance after first two cycles of neoadjuvant treatments |
| Secondary | pCR rate | 6 months after neoadjuvant treatment initation | After completion of neoadjuvant therapy and surgery, no residual invasive carcinoma in the evaluation of hematoxylin and eosin stained mamtectomy samples and all ipsilateral lymph node samples |
| Secondary | bpCR rate | 6 months after neoadjuvant treatment initation | After completion of neoadjuvant therapy and surgery, no residual invasive carcinoma in the evaluation of hematoxylin and eosin stained breast samples |
| Secondary | ORR | 6 months after neoadjuvant treatment initation | The proportion of patients whose tumor volume shrinks to a prespecified value and is able to maintain the minimum time limit, defined as the sum of the proportion of complete response (CR) and partial response (PR, with a reduction in tumor length and diameter greater than 30%). |
| Secondary | EFS | 2 years after surgery | The time interval from randomization to the first recording of the following events: disease progression (before surgery), as determined by investigator reference RECIST1.1, combined with clinical evaluation, final judgment; postoperative disease recurrence (local, regional, distal, or contralateral); second primary malignancy; Death from any cause |
| Secondary | DFS | 2 years after surgery | The time interval from the first date of disease-free (i.e., the date of surgery) to the first recording of the following events; Postoperative disease recurrence (local, regional, distal, or contralateral); second primary malignancy; Death from any cause. |
| Secondary | OS | 5 years after surgery | Time interval from randomization to death from any cause. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07335081
GET https://conductscience.org/api/trials/v1/NCT07335081/registered